Residual disease in acute lymphoblastic leukemia of childhood: Methods of detection and clinical relevance

Cytokines, Cellular and Molecular Therapy

Volumn 4, Issue 2, 1998, Pages 73-85

  Faderl, Stefan ^a   Estrov, Zeev ^a,b  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Childhood acute lymphoblastic leukemia; Clinical complete remission; Leukemia relapse; Polymerase chain reaction; Residual disease

Indexed keywords

TUMOR MARKER;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER REGRESSION; CELL CULTURE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE REARRANGEMENT; HUMAN; IMMUNOPHENOTYPING; KARYOTYPE; METHODOLOGY; MINIMAL RESIDUAL DISEASE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR GENE; REVIEW; SOUTHERN BLOTTING;

CELL CULTURE TECHNIQUES; CHILD; HUMANS; IMMUNOPHENOTYPING; KARYOTYPING; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION;

EID: 0031874143     PISSN: 13684736     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (157)

1. Rivera GK, Crist WM, Acute lymphoblastic leukemia. In: Blood, Principles and Practices of Hematology, 1st edn (ed RI Handin, SE Lux, TP Stossel) 743-82. JB Lippincott, Philadelphia, 1995.
2. Pinkel D, Lessons from 20 years of curative therapy of childhood acute leukaemia. Br J Cancer (1992) 65: 148-53.
3. Rivera GK, Pinkel D, Simone JV et al, Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital N Engl J Med (1993) 329. 1289-95.
4. Pui CH, Dodge RK, Look AT et al, Risk of adverse events in children completing treatment for acute lymphoblastic leukemia: St Jude Total Therapy Studies VIII, IX, and X. J Clin Oncol (1991) 9: 1341-7.
5. Bennett JM, Catovsky D, Daniel MT et al, The French-American-British (FAB) Cooperative Group Proposals for the classification of the acute leukaemias. Br J Haematol (1996) 33: 451-8.
6. Cheson BD, Cassileth PA, Head DR et al, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol (1990) 8: 813-18.
7. Cole-Sinclair MF, Foroni L, Hoffbrand AV, Genetic changes: relevance for diagnosis and detection of minimal residual disease in acute lymphoblastic leukaemia. Bailhère's Clin Haematol (1994) 7: 183-233.
8. Campana D, Pui CH, Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood (1995) 6: 1416-34.
9. Ryan DH, Van Dongen JJM, Detection of residual disease in acute leukemia using immunological markers. In: Immunologic Approaches to the Classification and Management of Lymphomas and Leukemias (ed JM Bennett, KA Foon) 173-207. Kluwer, Norwell, MA, 1988.
10. Van Bekkum DW, Reflection on the detection and treatment of leukemia. In: Minimal Residual Disease in Acute Leukemia (ed B Löwenberg, A Hagcnbeek) 385-90 Martinus Nijhoff, Boston, 1984.
11. Salloum E, Pico JL, Herait P et al, Very late recurrence of childhood acute lymphoblastic leukemia treated with chemoimmunotherapy: a report of three cases ocurring 19, 11 and 9 years after discontinuation of chemotherapy. Med Pediatr Oncol (1989) 17: 155-8.
12. Nizet Y, Van Daele S, Lewalle P et al, Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood (1993) 82: 1618-25.
13. Potter MN, Steward CG, Oakhill A, The significance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol (1993) 83: 412-18.
14. Rhagavachar A, Thiel E, Bartram CR, Analysis of phenotype and genotype in acute lymphoblastic leukemia at presentation and relapse. Blood (1987) 70: 1083-97.
15. Estrov Z, Grunberger T, Dubé ID et al, Detection of residual acute lymphoblastic leukemia cells in cultures of bone marrow obtained during remission. N Engl J Med (1986) 315: 538-42.
16. Roberts WM, Estrov Z, Kitchingman GR et al, Detection of minimal residual disease in ALL: biology, methods, and applications. In: Molecular Genetics and Therapy of Leukemia (ed EJ Freireich, H Kantarjian) 149-66. Kluwer, Boston, 1996.
17. Van Dongen JJM, Breit TM, Adriaansen HJ et al, Immunophenorypic and immunogenotypic detection of minimal residual disease in acute lymphoblastic leukemia. In: Recent Results in Cancer Research (ed WD Ludwig, E Thiel) 157-84. SpringerVerlag, Berlin, 1993.
18. Rogers PCJ, Bleyer WA, Coccia P et al, Yield of unpredicted bone marrow relapse diagnosed by routine marrow aspiration in children with acute lymphoblastic leukaemia. A report from the Children's Cancer Study Group. Lancet (1984) i: 1320-2.
19. Haworth C, Heppleston AD, Morris-Jones PH et al, Routine bone marrow examination in the management of acute Iymphohlastic leukaemia of childhood. J Clin Pathol (1981) 34: 483-5
20. Komp DM, Fischer DB, Sabio H et al, Frequency of bone marrow aspirates to monitor acute lymphoblastic leukaemia in childhood. J Pediatr (1983) 102: 395-7.
21. Borella L, Green AA, Webster RG, Immunological rebound after cessation of long-term chemotherapy in acute leukemia. Blood (1973) 40: 42-51.
22. Bradstock KF, Papageorgiou ES, Janossy G, Diagnosis of meningeal involvement in patients with acute lymphoblastic leukaemia: immunofluorescence for terminal transferase. Cancer (1981) 47: 2478-81.
23. Bernell P, Arvidsson I, Jacobson B et al, Fluorescence in situ hybridization in combination with morphology detects minimal residual disease in remission and heralds relapse in acute leukaemia. Br J Haematol (1996) 95: 666-72.
24. Wang JCY, Beauregard P, Soamboonsrup P et al, Monoclonal antibodies in the management of acute leukemia. Am J Hematol (1995) 50: 188-99.
25. Campana D, Coustan-Smith G, The immunologic detection of minimal residual disease in acute leukemia. Blood (1990) 76: 163-71.
26. Terstappen LWMM, Loken MR, Five dimensional flow cytometry as a new approach for blood and bone marrow differentials. Cytometry (1988) 9: 548-53.
27. Campana D, Coustan-Smith E, The use of flow cytometry to detect minimal residual disease in acute leukemia. Eur J Histochem (1996) 40(S1): 39-42.
28. Campana D, Coustan-Smith E, Behm FG, The definition of remission in acute leukemia with immunologic techniques. Bone Marrow Transplant (1991) 8: 429-37.
29. Janossy G, Campana D, Burnett A et al, Autologous bone marrow transplantation in acute lymphoblastic leukemia -preclinical immunologic studies. Leukemia (1988) 2: 485-95.
30. Campana D, Yokota S, Coustan-Smith E et al, The detection of residual acute lymphoblastic leukemia cells with immunologic methods and polymerase chain reaction. Leukemia (1990) 4: 609-14.
31. Cross HJ, Verwer B, Houck D et al, Detection of rare cells at a frequency of one per million by flow cytometry. Cytometry (1993) 14: 519-24
32. Rhese MA, Corpuz S, Heimfeld S et al, Use of fluorescence threshold triggering and high-speed flow cytometry for rare event detection. Cytometry (1995) 22: 317-22
33. Greaves MF, Delia D, Janossy G et al, Acute lymphoblastic leukaemia associated antigens. IV. Expression on non-leukaemic lymphoid cells. Leuk Res (1980) 4: 15-21.
34. Janossy G, Bollum FJ, Bradstock KF et al, Cellular phenotypes of normal and leukemic hemopoietic cells determined by analysis with selected antibody combinations. Blood (1980) 56: 430-41.
35. Greaves MF, Differentiation-linked leukemogenesis in lymphocytes. Science (1986) 234: 697-704.
36. Van Dongen JJM, Breit TM, Adriaansen HJ et al, Detection of minimal residual disease in acute leukemia by immunological marker analysis and polymerase chain reaction. Leukemia (1992) 6(S1): 47-59.
37. Reading CL, Estey EH, Huh YO et al, Expression of unusual immunophenotype combinations in acute myelogenous leukemia. Blood (1993) 81: 3083-7.
38. Hurwitz CA, Gore SD, Stone KD et al, Flow cytometric detection of rare normal human marrow cells with immunophenotypes characteristic of acute leukemia cells. Leukemia (1992) 6: 233-8.
39. Janossy G, Tidman M, Papageorgiou ES et al, Distribution of T lymphocyte subsets in the human bone marrow and thymus, an analysis with monoclonal antibodies. J Immunol (1981) 126: 1608-13.
40. + cells in the blood and bone marrow: implications for surveillance of residual leukemia. Blood (1989) 74: 312-19.
41. Campana D, Thompson JS, Amlot P et al, The cytoplastic expression of CD3 antigens in normal and malignant cells of T lymphoid lineage J Immunol (1987) 138: 648-55.
42. Campana D, Applications of cytometry to study acute leukemia: in vitro determination of drug sensitivity and detection of minimal residual disease Cytometry (1994) 18. 68-74.
43. Vogler LB, Grist WM, Bockman DE et al, Pre-B leukaemia: a new phenotype of childhood lymphoblastic leukaemia. N Engl J Med (1978) 298: 872-7.
44. Michiels J, Adriaansen HJ, Hagemeijer A et al, TdT positive B-cell acute lymphoblastic leukemia (B-ALL) without Burkitt characteristics. Br J Haematol (1988) 68: 423-6.
45. Potter MN, Cross NC, Van Dongen JJM et al, Molecular evidence of minimal residual disease after treatment for leukemia and lymphoma: an update meeting report and review Leukemia (1993 7: 1302-14.
46. Foot ABM, Potter MN, Ropner JE et al, Transient erythroblastopenia of childhood with CD10, TdT, and cytoplasmic μ lymphocyte positivity in bone marrow. J Clin Pathol (1990) 43: 857-9.
47. Hooijkaas H, Hählen K, Adriaansen HJ et al, Terminal deoxynucleotidyl transferase (TdT)-positive cells in cerebrospinal fluid and development of overt CNS leukemia: a 5-year follow-up study in 113 children with a TdT-positive leukemia or non-Hodgkin's lymphoma. Blood (1989) 74: 416-22.
48. Homans AC, Barker BE, Forman EN et al, Immunophenotypic characteristics of cerebrospinal fluid cells in children with acute lymphoblastic leukemia at diagnosis. Blood (1990) 76: 1807-11.
49. Pui CH, Raimondi SC, Behm FG et al, Shifts in blast cell phenotype and karvotype at relapse of childhood lymphoblastic leukemia Blood (1986) 68: 1306-10.
50. Bernard A, Raynal B, Lemeri J et al, Changes in surface antigens on malignant T cells from lymphoblastic lymphomas at relapse: an appraisal with monoclonal antibodies and micro-fluorometry. Blood (1982) 59: 809-15.
51. Stass S, Mirro J, Melvin S et al, Lineage switch in acute leukemia. Blood (1984) 64: 701-6s.
52. Martens ACM, Schulte FW, Hagenbeek A et al, Nonhomogenous distribution of leukemia in the bone marrow during minimal residual disease. Blood (1987) 70: 1073-8.
53. Cavé H, Guidai C, Rohrlich P et al, Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of 8 and γ T-cell receptor genes. Blood (1994) 83: 1892-902.
54. Anderson CL, Looney RJ, Human leukocyte IgG Fc receptors. Immunol Today (1986) 7: 264-6.
55. Seeker-Walker LM, Prentice HG, Durrant J et al, Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKATT. XA. Br J Haematol (1997) 96: 601-10.
56. Seeker-Walker LM, Lawler SD, Hardisty RM, Prognostic implications of chromosomal findings in acute lymphoblastic leukemia at diagnosis. Br Med J (1978) 2: 1529-30.
57. Williams DL, Raimondi S, Rivera G et al, Presence of clonal chromosome abnormalities in virtually all cases of acute lymphoblastic leukemia. N Engl J Med (1985) 313: 640-1 (letter).
58. Hart JS, Trujillo JM, Freireich EJ et al, Cytogenetic studies and their clinical correlates in adults with acute leukemia. Ann Intern Med (1971) 75: 353-60.
59. Mancini M, Nanni M, Cedrone M et al, Combined cytogenetic, FISH, and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission. Br J Haematol (1995) 91: 878-84.
60. Nowell P, Molecular monitoring of pre-B acute lymphoblastic leukaemia, J Clin Oncol (1987) 5: 692-3.
61. Freireich EJ, Cork A, Stass SA et al, Cytogenetics for detection of minimal residual disease in acute myeloblastic leukemia. Leukemia (1992) 6: 500-6.
62. Seeker-Walker LM, Leukaemia Research Fund International Research Symposium: Chromosomes and Genes in Leukaemia. Leukemia (1988) 2: 176-80.
63. Johnson RT, Rao PN, Mammalian cell fusion: induction of premature chromosome condensation in interphase nuclei. Nature (1970) 226: 717-22.
64. Hittelman WN, Broussard L, Dosik G et al, Predicting relapse of human leukemia by means of premature chromosome condensation. N Engl J Med (1980) 303: 419-84.
65. Estrov Z, Roberts WM, Zipf T, Residual disease in acute lymphoblastic leukemia of childhood. Detection, quantitation, characterization and clinical significance. Int J Pediatr Hematol Oncol (in press).
66. Barlogie B, Raber MN, Schumann J et al, Flow cytometry in clinical cancer research. Cancer Res (1983) 43: 3982-8
67. Krishan A, Rapid cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol (1975) 66: 188-93.
68. Rabinovitch PS, Torres RM, Engel D, Simultaneous cell cycle analysis and two-colour surface immunofluorescence using 7-aminoactinomycin D and single laser excitation: applications to study cell activation and cell cycle of murine Ly- B cells, J Immunol (1986) 136: 2769-75.
69. Jensen IM, Ellegaard J, Hokland P, Differences in relative DNA content between human peripheral blood and bone marrow subpopulations - consequences for DNA index calculations. Cytometry (1993) 14: 936-42.
70. Nowak R, Oelschlägel U, Hofmann R et al, Detection of aneuploid cells in acute lymphoblastic leukemia with flow cytometry before and after therapy. Leuk Res (1994) 18: 897-901.
71. Tsurusawa M, Kaneko Y, Katano N et al, Flow cytometric evidence for minimal residual disease and cytological heterogeneities in acute lymphoblastic leukemia with severe hypodiploidy. Ann J Hematol (1989) 32: 42-9.
72. Arkesteijn GJA, Martens ACM, Hagenbeek A, Bivariate flow karotyping in human Philadelphia-positive chronic myelocytic leukemia. Blood (1988) 72: 282.
73. Gray JW, Kuo WL, Pinkel D, Molecular cytometry applied to detection and characterization of disease-linked chromosome aberrations. Baillière's Clin Haematol (1991) 4: 683-93.
74. Chen Z, Morgan R, Berger CS et al, Application of fluorescence in situ hybridization in hematological disorders. Cancer Genet Cytogenet (1992) 63: 62-9.
75. Cuneo A, Bigoni R, Roberti MG et al, Detection of numerical aberrations in hematologic neoplasias by fluorescence in situ hybridization. Haematologica (1997) 82: 85-90.
76. Pinkel D, Landegent J, Collins C et al, Fluorescence in situ hybridization with human chromosome-specific libraries: detection of trisomy 21 and translocations of chromosome 4. Proc. Natl Acad Sci USA (1988) 85: 9138-42.
77. Siciliano MJ, Fluorescence in situ hybridization: molecular cytogenetics. In: Molecular Biology in Cancer Medicine (ed R Kurzrock, M Talpaz) 27-37. Martin Dunitz, London, 1995.
78. Heerema NA, Argyropoulas G, Weetman R et al, Interphase in situ hydridization reveals minimal residual disease in early remission and return of the diagnostic clone in karyotypically normal relapse of acute lymphoblastic leukemia. Leukemia (1993) 7: 537-43.
79. Anastasi J, Le Beau MM, Vardiman JW et al, Detection of numerical chromosomal abnormalities in neoplastic hematopoietic cells by in situ hybridization with a chromosome-specific probe. Am J Pathol (1990) 136: 131-9.
80. Nylund SJ, Ruutu T, Saarinen U et al, Metaphase fluorescence in situ hybridization (FISH) in the follow-up of 60 patients with haematopoietic malignancies. Br J Haematol (1994) 88: 778-83.
81. Tkachuk DC, Westbrook CA, Andreeff M et al, Detection of bcr-abl fusion in chronic myelogenous leukemia by in situ hybridization. Science (1990) 250: 559-62.
82. El-Rifai W, Ruutu T, Vettenranta K et al, Minimal residual disease after allogeneic bone marrow transplantation for chronic myeloid leukemia: a metaphase-FISH study. Br J Haematol (1996) 92: 365-9.
83. Arnoldus EPJ, Wiegant J, Noordermeer IA et al, Detection of the Philadelphia chromosome in interphase nuclei. Cytogenet Cell Genet (1990) 54: 108-11.
84. Raimondi SC, Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood (1993) 81: 2237-51.
85. Gray JW, Huo WK, Liang J et al, Analytical approaches to detection and characterization of disease-linked chromosome aberrations. Bone Marrow Transplant (1990) 6: 14-19.
86. Seong D, Giralt S, Fischer et al, Usefuleness of detection of minimal residual disease by 'hypermetaphase' fluorescent in situ hybridization after allogeneic BMT for chronic myelogenous leukemia. Bone Marrow Transplant (1997) 19: 565-70.
87. White DM, Crolla J, Ross F, Detection of minimal residual disease in childhood acute lymphoblastic: leukaemia using fluorescent insitu hybridization. Br J Haematol (1996) 92: 88-96.
88. Weber-Matthiesen K, Winkemann M, Müller-Hermelink A et al, Simultaneous fluorescence immunophenotyping and interphase cytogenetics: a contribution to the characterization of tumor cells. J Histochem Cytochem (1992) 40: 171-5.
89. Anastasi J, Vardiman JW, Rudinsky R et al, Direct correlation of cytogenetic findings with cell morphology using in situ hybridization: an analysis of suspicious cells in bone marrow specimens of two patients completing therapy for acute lymphoblastic leukemia. Blood (1991) 11. 2456-62.
90. Mehrotra B, George TI, Kavanau K et al, Cytogenetically aberrant cells in the stem cell compartment (CD34+lin-) in acute myeloid leukemia. Blood (1995) 86: 1139-47.
91. Kaspryzyk A, Seckler-Walker LM, Increased sensitivity of minimal residual disease detection by interphase FISH in acute lymphoblastic leukemia with hyperdiploidy. Leukemia (1997) 11: 429-35.
92. Southern EM, Detection of specific sequences among DNA fragments separated by gel electrophorresis. J Mol Evol (1975) 98: 503-17.
93. Van Dongen JJM, Wolvers-Tettero ILM, Analysis of T immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. Clin Chim Acta (1991) 198: 1-92.
94. Cleary ML, Chao J, Warnke R et al, Immunoglobulin gene rearrangement as a diagnostic criterion of B-cell lymphoma. Proc Natl Acad Sci USA (1984) 81: 593-7.
95. Yoffe G, Blick M, Kantarjian H et al, Molecular analysis of interferon-induced suppression of Philadelphia chromosome in patients with chronic myelogenous leukemia. Blood (1987) 69: 961-3.
96. Bregni M, Siena S, Neri A et al, Minimal residual disease in acute lymphoblastic leukemia J Clin Oncol (1989) 7: 338-43.
97. Zehnbauer BA, Pardoll DM, Burke PJ et al, Immunoglobulin gene rearrangements in remission bone marrow specimens from patients with acute lymphoblastic leukemia. Blood (1986) 67: 835-8.
98. Saiki RK, Scharf S, Faloona F et al, Enzymatic amplification of β-globin genomic sequences and restriction site analysis of sickle cell anaemia. Science (1985) 230: 1350-4.
99. Saiki RK, Gelfand DH, Stoffel S et al, Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science (1988) 239: 487-91.
100. D'Auriol L, Macintyre E, Galibert F et al, In vitro amplification of T cell γ gene rearrangemts: a new tool for the assessment of minimal residual disease in acute lymphoblastic leukemia. Leukemia (1989) 3: 155-8.
101. Hansen-Hagge TE, Yokota S, Bartram CR, Detection of minimal residual disease in acute lymphoblastic leukemia by in vitro amplification of rearranged T-cell receptor δ chain sequences. Blood (1989) 74: 1762-7.
102. Yamada M, Hudson S, Tournay O et al, Detection of minimal residual disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes. Proc Natl Acad Sci USA (1989) 86: 5123-7.
103. Lee MA, Chang KS, Cabanillas F et al, Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification. Science (1987) 237: 175-8
104. Crescenzi M, Seto M, Herzig GP et al, Thermostable DNA polymerase chain amplification of the t(14;18) chromosome break-points and detection of minimal residual disease. Proc Nail Acad Sci USA (1988) 45: 4869-73.
105. White TJ, Arnheim N, Erlich HA, The polymerase chain reaction. Trends Genet (1989) 5: 185-9.
106. Roberts WM, Estrov Z, Ouspenskaia MV et al, Measurement of residual leukemia during remission childhood acute lymphoblastic leukemia. N Engl J Med (1997) 336: 317-23.
107. Sklar J, Polymerase chain reaction: the molecular microscope of residual disease. J Clin Oncol (1991) 9: 1521-4.
108. Human Gene Mapping 8. Helsinki Conference: Eighth International Workshop on Human Gene Mapping. Cytogenei Cell Genet (1985) 40: 156-78, 206-41.
109. Berman JE, Mellis SJ, Pollock et al, Content and organization of the human Ig VH locus: definition of three new VH families and linkage to the Ig CH locus. EMBO J (1988) 7: 727-39.
110. Tonegawa S, Somatic generation of antibody diversity. Nature (1983) 302: 575-81.
111. Abbas AK, Lichtman AH, Pober JS, Maturation of B lymphocytes and expression of immunoglobulin genes. In: Cellular and Molecular Immunology, 3rd edn: 67-95. WB Saunders, Philadelphia, 1997
112. Ichihara Y, Matsuoka H, Kurosawa Y, Organization of human immunoglobulin heavy chain diversity gene loci. EMBO J (1988) 7: 4141-50.
113. Bakkus MHC, Juge-Morineau N, Van der Werff ten Bosch JE, Detection of minimal residual disease in multiple myeloma and acute leukemia. Med Oncol (1996) 13: 121-31.
114. Jonsson OG, Kitchens RL, Scott FC et al, Detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin hypervariable specific oligonucleotide probes. Blood (1990) 76: 2072-9
115. Brisco MJ, Tan LW, Orsborn AM et al, Development of a highly sensitive assay based on the polymerase chain reaction for rare B-lymphocyte clones in a polyclonal population. Br J Haematol (1990) 75: 163-7.
116. Van Dongen JJM, Wolvers-Tettero ILM, Analysis of immunoglobulin and T cell receptor genes. Part II: Possibilities and limitations in the diagnosis and management of lymphoproliferative disease and related disorders. Clin Chim Acat (1991) 27: 1481-6.
117. Felix CA, Poplack DG, Reaman GH et al, Characterization of immunoglobulin and T-cell receptor gene patterns in B-cell precursor acute lymphoblastic leukemia of childhood. J Clin Oncol (1990) 8: 431-42.
118. Beishuizen A, Verhoeven MA, Hahlen K et al, Differences in immunoglobulin heavy chain gene rearrangement patterns between bone marrow and blood samples in childhood precursor B-acute lymphoblastic leukemia at diagnosis. Leukemia (1991) 5: 657-67.
119. Breit TM, Wolvers-Tettero ILM, Beishuizen A et al, Southern blot patterns, frequencies and functional diversity of T-cell receptor δ gene rearrangements in acute lymphoblastic leukemia. Blood (1993) 82: 3063-74.
120. Katz F, Ball L, Gibbons B et al, The use of DNA probes to monitor minimal residual disease in childhood acute lymphoblastic leukaemia. Br J Haematol (1989) 73: 173-80.
121. Bird J, Galili N, Link M et al, Continuing rearrangement but absence of somatic hypermutation in immunoglobulin genes of human B cell precursor leukemia. J Exp Med (1988) 168: 229-45
122. Beishuizen A, Verhoeven MAJ, van Wering ER et al, Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood (1994) 83: 2238-47.
123. Steward CG, Goulden NJ, Katz F et al, A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of childhood B-lineage acute lymphoblastic leukemia. Blood (1994) 83: 1355-62.
124. Norris MD, Kwan E, Haber M et al, Detection of evolving immunoglobulin heavy-chain gene rearrangements in acute lymphoblastic leukemia: a PCR-bascd assay employing overlapping DJh primers, Leukemia (1995) 9: 1779-82.
125. Drexler HG, Borkhart A, Janssen JWG, Detection of chromosomal translocations in leukemia-lymphoma cells by polymerase chain reaction. Leuk Lymphoma (1995) 19: 359-80.
126. Bartram CR, Detection of minimal residual leukemia by the polymerase chain reaction: potential implications for therapy. Clin Chim Acta (1993) 217: 75-83.
127. Deane M, Hoffbrand AV, Detection of minimal residual disease in ALL. In: Leukemia: Advances in Research and Treatment (ed EJ Freireich, H Kantarjian) 136-70. Kluwer, Boston, 1993.
128. Erlich HA, Gelfand DH, Saiki RK, Specific DNA amplification. Nature (1985) 316: 817-19.
129. Chen Q, Cheng JT, Tsai LH et al, The tal gene undergoes chromosome translocation in T cell leukemia and potentially encodes a helix-loop-helix protein. EMBO J (1990) 9: 415-24.
130. Kagan J, Finger LR, Besa E et al, Detection of minimal residual disease in leukemic patients with the t(10;14)(q24;q11) chromosomal translocation. Cancer Res (1990) 50: 5240-4.
131. Maurer J, Janssen JWG, Thiel E et al, Detection of chimeric BCR-ABL genes in acute lymphoblastic leukemia by the polymerase chain reaction. Lancet (1991) 337: 1055-8.
132. Kawasaki ES, Clark SS, Coyne MY et al, Diagnosis of chronic myeloid and acute lympliocytic leukemia by detection of leukemia-specific mRNA sequence amplification in vitro. Proc Natl Acad Sci USA (1988) 85: 5698-702.
133. Gehly GB, Bryant EM, Lee AM et al, Chimeric BCR-abl messenger RNA as a marker for minimal residual disease in patients transplanted for Philadelphia chromsome-positive acute lymphoblastic leukemia. Blood (1991) 78: 458-65.
134. Privitera E, Rivolta A, Ronchetti D, et al, Reverse transcriptase/polymerase chain reaction follow-up and minimal residual disease detection in t(1;19)-positive acute lymphoblastic leukaemia. Br J Haematol (1996) 92: 653-8.
135. Cimino G, Elia L, Rivolta A et al, Clinical relevance of residual disease monitoring by polymerase chain reaction in patients with ALL-1/AF-4 positive acute lymphoblastic leukaemia. Br J Haematol (1996) 92: 88-96.
136. Shiramizu B, Magrath I, Localization of breakpoints by polymerase chain reactions in Burkitt's lymphoma with 8; 14 translocations. Blood (1990) 75: 1848-52.
137. Monica K, Galili N, Nourse J et al, PBX2 and PBX3, new homeobox genes with extensive homology to the human protooncogene PBX1. Mol Cell Biol (1991) 11: 6149-57.
138. Raynaud S, Cavé H, Baens M et al, The 12;21 translocation involving TEL and deletion of the other TEL aliele two frequently associated alterations found in childhood acute: lymphoblastic leukemia. Blood (1996) 87: 2891-9.
139. Billadeau D, Blackstadt M, Greipp P et al, Analysis of B-lymphoid malignancies using allele-specific polymerase chain reaction, a technique for sequential quantitation of residual disease. Blood (1991) 78: 3021-9.
140. Ouspenskaia MV, Johnston DA, Roberts WM et al, Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia (1995) 9: 321-8.
141. Cross NCP, Feng L, Chase A et al, Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood (1993) 82: 1929-36.
142. Malinge MA, Mahon FX, Delfau MH et al, Quantative determination of the bybrid Bcr-Abl RNA in patients with chronic myelogenous leukemia under Interferon therapy. Br J Haematol (1992) 22: 701-7.
143. Estrov Z, Freedman MH, Growth requirements for human acute lymphoblastic leukemia cells: refinement of a clonogenic assay. Cancer Res (1988) 48: 5901-7.
144. Ruey LH, Ssu WS, Ming TL et al, Lymphoblast colony culture assay in acute lymphoblastic leukemia: a quantitative approach. Leuk Res (1993) 17: 463-70.
145. Uckun FM, Kersey JH, Haake R et al, Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia. N Engl J Med (1993) 329: 1296-1301.
146. Kurzrock R, Talpaz M, Beran M et al, DNA in situ hybridization of individual colonies to determine lineage derivation in leukemia Leukemia (1998) 12: 242-6.
147. Estrov Z, Ouspenskaia MV, Felix EA et al, Persistence of self-renewing leukemia cell progenitors during remission in children with B-precursor acute lymphoblastic leukemia. Leukemia (1994) 8: 46-52.
148. Wasserman R, Galili N, Ito Y et al, Residual disease at the end of induction therapy as a predictor of relapse during therapy in childhood B-lineage acute lymphoblastic leukemia. J Clin Oncol (1992) 10: 1879-88.
149. Bnsco MJ, Condon J, Hughes E et al, Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of the induction. Lancet (1994) 343: 196-200.
150. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF et al, Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia (1995) 9: 1726-34.
151. Dibenedetto SP, Lo Nigro L, Pine Mayer S et al, Detectable molecular residual disease at the beginning of maintenance threapy indicates poor outcome in children with T-cell acute lymphoblastic leukemia. Blood (1997) 90: 1226-32.
152. Cole-Sinclair M, Foroni L, Wright F et al, Minimal residual disease in acute lymphoblastic leukaemia - PCR analysis of immunoglobulin gene rerrangements. Leuk Lymphoma (1993) 11 (S2): 49-58.
153. Biondo A, Yokota S, Hansen-Hagge TE et al, Minimal residual disease in childhood acute lymphoblastic leukemia: analysis of patients in continuous complete remission or with consecutive relapse. Leukemia (1992) 6: 282-8.
154. Kitchingman GR, Residual disease detection in multiple follow-up samples in children with acute lymphoblastic leukemia. Leukemia (1994) 8: 395-401
155. Ito Y, Wasserman R, Galili N et al, Molecular residual disease status at the end of chemotherapy fails to predict subsequent relapse in children with B-lineage acme lymphoblastic leukemia. J Clin Oncol (1993) 11: 546-53.
156. Neale GAM, Menarguez J, Kitchingman GR et al, Detection of minimal residual disease in T-cell acute lymphoblastic leukemia using polymerase chain reaction predicts impending relapse. Blood (1991) 78: 739-47.
157. Ito Y, Miyamura K, Clinical significance of minimal residual disease in leukemia detected by polymerase chain reaction: Is molecular remission a milestone for achieving a cure? Leuk Lymphoma (1994) 16: 57-64.